Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

806 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: outcomes from a single-institution series.
Johnston M, Guo L, Back M, Guminski A, Lee A, Hanna C, Veivers D, Wignall A, Eade T. Johnston M, et al. Among authors: back m. J Med Imaging Radiat Oncol. 2013 Jun;57(3):356-63. doi: 10.1111/1754-9485.12033. Epub 2013 Jan 17. J Med Imaging Radiat Oncol. 2013. PMID: 23721147 Clinical Trial.
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Gzell C, Wheeler H, Guo L, Kastelan M, Back M. Gzell C, et al. Among authors: back m. J Cancer Surviv. 2014 Mar;8(1):108-13. doi: 10.1007/s11764-013-0311-9. Epub 2013 Nov 9. J Cancer Surviv. 2014. PMID: 24214496
Data were collected on EM prior (EM pre) and after RT at 6 and 12 months (EM 6 m, EM 12 m). Rate of EM was analysed in regards to baseline performance status (ECOG), neurological deficits (MRC scale) and median survival. ...CONCLUSION: A modest proportion of patient …
Data were collected on EM prior (EM pre) and after RT at 6 and 12 months (EM 6 m, EM 12 m). Rate of EM was analysed in regards …
Neutrophil-to-lymphocyte ratio in head and neck cancer.
Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T. Haddad CR, et al. Among authors: back m. J Med Imaging Radiat Oncol. 2015 Aug;59(4):514-519. doi: 10.1111/1754-9485.12305. Epub 2015 Apr 23. J Med Imaging Radiat Oncol. 2015. PMID: 25908427
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H. Khasraw M, et al. Among authors: back m. J Neurooncol. 2016 May;128(1):163-171. doi: 10.1007/s11060-016-2094-0. Epub 2016 Mar 2. J Neurooncol. 2016. PMID: 26935578 Clinical Trial.
Radiotherapy in Glioblastoma: the Past, the Present and the Future.
Gzell C, Back M, Wheeler H, Bailey D, Foote M. Gzell C, et al. Among authors: back m. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):15-25. doi: 10.1016/j.clon.2016.09.015. Epub 2016 Oct 13. Clin Oncol (R Coll Radiol). 2017. PMID: 27743773 Review.
806 results